An Australian stem cell and regenerative medicine company

ASX Announcements

17 Nov 2017 Managing Director's Annual General Meeting Presentation
17 Nov 2017 Chairman's Annual General Meeting Address
14 Nov 2017 Company Investor Presentation
14 Nov 2017 Enrolment Completed in 1st Cohort of Cynata Clinical Trial
27 Oct 2017 September 2017 Quarterly Report
10 Oct 2017 Van Leeuwenhoeck Institute Updates Cynata Research Coverage
09 Oct 2017 Annual Report to Shareholders
09 Oct 2017 Notice of Annual General Meeting/Proxy Form
09 Oct 2017 Cynata to Increase Exposure in Japan
27 Sep 2017 US Patent Granted for Cynata Cymerus Technology
10 Sep 2017 HC Wainwright & Co Updates Cynata Research Coverage
31 Aug 2017 Health Canada Meeting Advances CYP Global Development Plans
24 Aug 2017 Appendix 4G
24 Aug 2017 Appendix 4E & Financial Statements
23 Aug 2017 Positive Data from CYP MSCs in 2nd Preclinical Asthma Study
07 Aug 2017 Appendix 3B
28 Jul 2017 June 2017 Quarterly Report
24 Jul 2017 NDF's Stuart Roberts Initiates Cynata Research Coverage
04 Jul 2017 FDA Meeting Provides Clear Path for US Development Plans
04 Jul 2017 Change of Address
27 Jun 2017 Cynata Therapeutics GvHD Clinical Trial & Corporate Progress
22 Jun 2017 CYP MSC Data in Asthma Model Published in Scientific Journal
20 Jun 2017 Cynata Files New Patent Application for Cymerus in Oncology
19 Jun 2017 United States Patent for Core Cynata Technology
06 Jun 2017 Van Leeuwenhoeck Institute Initiates CYP Research Coverage
04 Jun 2017 Appendix 3Y-Peter Webse
04 Jun 2017 Correction to date in Appendix 3Y Lodged 26 May 2017
29 May 2017 Cynata Investor Presentation May 2017
25 May 2017 Appendix 3Y-Paul Wotton
17 May 2017 Appendix 3Y-John Chiplin
15 May 2017 Treatment Commences in Cynata's World First Clinical Trial
10 May 2017 Interview with UK Chief Investigator in Cynata Clinical Trial
07 May 2017 Shaw & Partners Initiates Cynata Research Coverage
07 May 2017 Appendix 3Y-Paul Wotton
03 May 2017 Cyanta Presentation & Webcast
03 May 2017 Appendix 3Y-Stewart Washer
26 Apr 2017 March 2017 Quarterly Report
18 Apr 2017 Cynata Advances to Pre-IND Meeting with US FDA
11 Apr 2017 CYP Files for New Patent for Oncology Applications
10 Apr 2017 CYP in Collaboration on Acute Respiratory Distress Syndrome
03 Apr 2017 Appendix 3Y-Ross Macdonald
30 Mar 2017 Cynata Partner apceth GmbH & Co Completes Cymerus Evaluation
10 Mar 2017 Proactive Investor Conference Presentation
01 Mar 2017 CYP Advances Development of Cymerus for Treatment of Asthma
27 Feb 2017 Dr Paul Wotton Appointed as Chairman of Cynata
27 Feb 2017 Appendix 4D & Half-Year Financial Statements
24 Feb 2017 Change in substantial holding
19 Feb 2017 Becoming a substantial holder
05 Feb 2017 Final GvHD Preclinical Report Confirms Treatment Benefit
01 Feb 2017 Positive Preliminary Data from Preclinical Heart Attack Study